An interventional study of Daily watching videos using Reviview™, a dichoptic video display device, for 60 min in Amblyopia, sponsored by Visior Technologies Ltd.. Completed at 1 site in Israel. Open to participants aged 4 Years to 8 Years. Per ClinicalTrials.gov, last updated 2017-07-21.
Sponsored by Visior Technologies Ltd. · Not applicable, Interventional, and Treatment
The study will evaluate the effect of Reviview™, a dichoptic video display device for administrating a novel treatment protocol for Amblyopia (lazy eye) in kids.
The effect of the treatment will be measured by the change from baseline in Visual acuity and in Stereoscopic Vision; and to assess the ease of use of and compliance by the patients.
183 studies on the registry are indexed under Amblyopia; 43 are open to participants now.
This study's enrollment of 35 is below the median of 60 across 133 interventional studies indexed under Amblyopia.
Browse Amblyopia studies →Visior Technologies Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Refractive or Strabismic Amblyopia, with best corrected visual acuity.
(1) Refractive Amblyopia, visual acuity score \<6:15 (worse then)
Exclusion Criteria:
Diagnosed with epilepsy, recently treated with occlusion or penalization therapy
Daily watching videos using Reviview™, a dichoptic video display device
Device: Daily watching videos using Reviview™, a dichoptic video display device, for 60 min
Improvement in VA in amblyopic eye
Time frame: 3 months
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Visior Technologies Ltd.